급성 편두통 치료를 위한 글루탐산 수용체 길항제의 임상적 유효성에 대한 메타분석
Meta-analysis on the Efficacy of Glutamate Receptor Antagonists for Acute Migraine Treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Glutamate is implicated in the pathophysiology of migraine, a common neurological disorder. Therefore, glutamate receptor antagonists (GluRAs) have been suggested as a novel migraine treatment that are able to overcome the limitations of triptans. Objective: The aim of this study was to perform a meta-analysis to assess the efficacy of GluRAs for patients with migraine. Method: The PubMed, Cochrane Library, CINAHL, and Clinical Trial.gov databases were searched for randomized placebo-controlled trials of the efficacy of GluRAs for patients with migraine conducted up to August 2019. Two independent reviewers screened the literature according to inclusion and exclusion criteria and performed quality assessment and data extraction. Review Manager 5.3 software was used for the meta-analysis. Results: Three studies involving a total of 206 patients were included in the final analysis. Compared with placebo, GluRAs significantly improved the pain-free response at 2 hours (odds ratio [OR]=3.85, 95% confidence intervals [CIs]=1.63-9.09) and the 24-hour sustained pain freedom (OR=7.40; 95% CIs=2.36- 23.20). The use of rescue medications with GluRAs was lower compared to that with placebo, but the difference was not significant (OR=0.39, 95% CI=0.10-1.47). Conclusion: Our meta-analysis showed that GluRAs were more effective than placebo for patients with migraine.
Abstract
Background: Glutamate is implicated in the pathophysiology of migraine, a common neurological disorder. Therefore, glutamate receptor antagonists (GluRAs) have been suggested as a novel migraine treatment that are able to overcome the limitations of triptans. Objective: The aim of this study was to perform a meta-analysis to assess the efficacy of GluRAs for patients with migraine. Method: The PubMed, Cochrane Library, CINAHL, and Clinical Trial.gov databases were searched for randomized placebo-controlled trials of the efficacy of GluRAs for patients with migraine conducted up to August 2019. Two independent reviewers screened the literature according to inclusion and exclusion criteria and performed quality assessment and data extraction. Review Manager 5.3 software was used for the meta-analysis. Results: Three studies involving a total of 206 patients were included in the final analysis. Compared with placebo, GluRAs significantly improved the pain-free response at 2 hours (odds ratio [OR]=3.85, 95% confidence intervals [CIs]=1.63-9.09) and the 24-hour sustained pain freedom (OR=7.40; 95% CIs=2.36- 23.20). The use of rescue medications with GluRAs was lower compared to that with placebo, but the difference was not significant (OR=0.39, 95% CI=0.10-1.47). Conclusion: Our meta-analysis showed that GluRAs were more effective than placebo for patients with migraine.
참고문헌 (21)
- 김병건, "Prevalence and Impact of Migraine and Tension-Type Headache in Korea", Journal of Clinical Neurology, 8(3), pp.204~211 (2012), 대한신경과학회[DOI]
- Sun Mi Kim, "The Development of Evidence-Based Guideline for Diagnosis and Management of Headache in Korea", PSYCHIATRY INVESTIGATION, 16(3), pp.199~205 (2019), 대한신경정신의학회[DOI]
- Derry CJ, "Sumatriptan (oral route of administration) for acute migraine attacks in adults", Cochrane Database Syst Rev, 2012(2), pp.CD008615~ (2012)
- Antonaci F, "Recent advances in migraine therapy", SpringerPlus, 5, pp.637~ (2016)
- 주민경, "편두통의 진단과 치료", Korean Journal of Family Medicine, 27(6), pp.425~435 (2006), 대한가정의학회
- Chung CS, "Drug therapy for migraine", J Korean Med Assoc, 50(10), pp.917~923 (2007)
- Diener HC, "New therapeutic approaches for the prevention and treatment of migraine", Lancet Neurol, 14, pp.1010~1022 (2015)
- Chan K, "Glutamate receptor antagonists in the management of migraine", Drugs, 74, pp.1165~1176 (2014)
- Hoffmann J, "Glutamate and its receptors as therapeutic targets for migraine", Neurotherapeutics, 15, pp.361~370 (2018)
- Andreou AP, "Therapeutic potential of novel glutamate receptor antagonists in migraine", Expert Opin Investig Drugs, 18(6), pp.789~803 (2009)
- Ferrari A, "Glutamate receptor antagonists with the potential for migraine treatment", Expert Opin Investig Drugs, 06(12), pp.1321~1330 (2017)
- Monteith D, "Phase 2 trial of LY2300559 for treatment of acute migraine headaches", Cephalalgia, 33(11), pp.981~ (2013)
- Sang CN, "LY293558, a novel AMPA", GluR5 antagonist, is efficacious and well-tolerated in acute migraine, 2004, pp.24, 596~602
- Gomez-Mancilla B, "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks", Cephalalgia, 34(2), pp.103~113 (2014)
- Waung MW, "Metabotropic glutamate receptor 5: a target for migraine therapy", Ann Clin Transl Neurol, 3(8), pp.560~571 (2016)
- Lupi C, "Pharmacokinetics and pharmacodynamics of new acute treatments for migraine", Expert Opin Drug Metab Toxicol, 15(3), pp.189~198 (2019)
- Headache Classification Committee of the International Headache Society, "The international classification of headache disorders (second edition)", Cephalalgia, 24(Suppl 1), pp.1~160 (2004)
- Diener HC, "Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition", Cephalalgia, 39(6), pp.687~710 (2019)
- Tfelt-Hansen P, "Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators", Cephalalgia, 32(1), pp.6~38 (2012)
- 강현, "메타분석에서 통계학적 고려사항들", Hanyang Medical Reviews, 35(1), pp.23~32 (2015), 한양대학교 의과대학[DOI]
- Kim SY, "NECA’s guidance for undertaking systematic reviews and meta-analyses for intervention", National Evidence-based Healthcare Collaborating Agengy, 129~199 (2011)